Curiously, ER+ BC patients had a significantly higher percentage of LDN, when compared to HER2 (p = 0.0007, Figure 1C) and TNBC (p = 0.0451, Figure 1C), highlighting that the assessment of LDN could be a crucial tool in determining, in advance, the response to treatment, especially for ER+ patients. This evidence concerns the gene ESR1 and breast cancer.